Predictive Oncology (NASDAQ:POAI) Shares Cross Below 200-Day Moving Average – Here’s What Happened

Predictive Oncology Inc. (NASDAQ:POAI) shares passed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $10.47 and traded as low as $6.52. Predictive Oncology shares last traded at $6.7596, with a volume of 40,332 shares changing hands.

Analyst Upgrades and Downgrades

A number of equities analysts have commented on POAI shares. Wall Street Zen lowered shares of Predictive Oncology to a “strong sell” rating in a report on Saturday, December 6th. Weiss Ratings restated a “sell (e+)” rating on shares of Predictive Oncology in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has an average rating of “Sell”.

Predictive Oncology Price Performance

The firm has a market cap of $22.94 million, a P/E ratio of -0.50 and a beta of 1.35. The firm’s 50-day moving average price is $6.22 and its 200 day moving average price is $10.47.

Predictive Oncology (NASDAQ:POAI) last announced its quarterly earnings data on Friday, November 14th. The medical instruments supplier reported ($4.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.35) by ($3.17). The firm had revenue of $0.00 million for the quarter, compared to analyst estimates of $1.50 million. Predictive Oncology had a negative net margin of 5,065.23% and a negative return on equity of 732.73%. Analysts forecast that Predictive Oncology Inc. will post -2.08 earnings per share for the current year.

About Predictive Oncology

Predictive Oncology, Inc is a biotechnology company that leverages artificial intelligence and digital biology to support drug discovery and development in oncology. Its core business revolves around the application of machine learning algorithms to high-content cellular imaging, multi-omic profiling, and clinical response data. By integrating these diverse data streams, the company aims to generate predictive models that forecast the efficacy and toxicity of candidate therapeutics, thereby accelerating preclinical decision-making and reducing development timelines.

The company’s primary offerings include its Phenomics platform, which combines automated microscopy with advanced image analysis to capture subtle phenotypic changes in cancer cells.